Ya. A. Ivanenkov, S. Yu. Maklakova, E. K. Beloglazkina, N. V. Zyk, A. G. Nazarenko, A. G. Tonevitsky, V. E. Kotelianski, A. G. Majouga, “Development of liver cell-targeted drug delivery systems: experimental approaches”, Usp. Khim., 2017, Volume 86, Issue 8,Pages <nobr>750

This article is cited in 17 papers

Development of liver cell-targeted drug delivery systems: experimental approaches

Ya. A. Ivanenkov^ab, S. Yu. Maklakova^a, E. K. Beloglazkina^a, N. V. Zyk^a, A. G. Nazarenko^c, A. G. Tonevitsky^de, V. E. Kotelianski^f, A. G. Majouga^agc

^a Lomonosov Moscow State University, Faculty of Chemistry
^b Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow region
^c Clinical Hospital of General Management Department of the President of Russian Federation, Moscow
^d SNC Bioclinicum
^e P. A. Gertsen Moscow Research Oncology Institute, Moscow
^f Skolkovo Institute of Science and Technology
^g National University of Science and Technology «MISIS»

Abstract: The review is devoted to liver cell-targeted drug delivery systems. Primary attention is paid to the therapy of hepatocellular carcinoma, liver fibrosis, liver cirrhosis, viral hepatitis (A–G), cholangiocarcinoma, autoimmune liver diseases and some metabolic disorders. A general overview, modern classification and specific features of drug delivery systems are presented. The key characteristics and parameters of these systems and their advantages and restrictions for clinical applications are discussed. A considerable body of information is presented as summary tables convenient for perception and comparison. The data presented are critically analyzed and an expert evaluation of the therapeutic potential of the drug delivery systems in question is given. Discussion of invasive local delivery approaches, transmembrane systems and implants, as well as prodrugs is beyond the scope of the review, except for a few examples.
The bibliography includes 344 references.

Received: 27.10.2016

DOI: 10.1070/RCR4707